Published in Clin Infect Dis on April 17, 2013
Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI). Clin Infect Dis (2015) 3.21
Single-molecule sequencing to track plasmid diversity of hospital-associated carbapenemase-producing Enterobacteriaceae. Sci Transl Med (2014) 2.87
The global threat of antimicrobial resistance: science for intervention. New Microbes New Infect (2015) 2.45
The global challenge of carbapenem-resistant Enterobacteriaceae in transplant recipients and patients with hematologic malignancies. Clin Infect Dis (2014) 1.94
The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria. Clin Microbiol Rev (2015) 1.81
New antibiotics for bad bugs: where are we? Ann Clin Microbiol Antimicrob (2013) 1.58
Antimicrobial activity of ceftazidime-avibactam against Gram-negative organisms collected from U.S. medical centers in 2012. Antimicrob Agents Chemother (2013) 1.53
New β-lactamase inhibitors: a therapeutic renaissance in an MDR world. Antimicrob Agents Chemother (2013) 1.47
Antibiotics and bacterial resistance in the 21st century. Perspect Medicin Chem (2014) 1.41
Antimicrobial resistance: risk associated with antibiotic overuse and initiatives to reduce the problem. Ther Adv Drug Saf (2014) 1.35
Unexpected challenges in treating multidrug-resistant Gram-negative bacteria: resistance to ceftazidime-avibactam in archived isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother (2014) 1.24
Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations. Clin Infect Dis (2016) 1.12
Trends and seasonal variation in outpatient antibiotic prescription rates in the United States, 2006 to 2010. Antimicrob Agents Chemother (2014) 1.11
ESKAPEing the labyrinth of antibacterial discovery. Nat Rev Drug Discov (2015) 1.09
The evolving role of chemical synthesis in antibacterial drug discovery. Angew Chem Int Ed Engl (2014) 1.05
High-copy bacterial plasmids diffuse in the nucleoid-free space, replicate stochastically and are randomly partitioned at cell division. Nucleic Acids Res (2013) 1.04
Metabolic suppression identifies new antibacterial inhibitors under nutrient limitation. Nat Chem Biol (2013) 1.04
Investigational antimicrobial agents of 2013. Clin Microbiol Rev (2013) 1.04
Variants of β-lactamase KPC-2 that are resistant to inhibition by avibactam. Antimicrob Agents Chemother (2015) 1.03
The β-Lactams Strike Back: Ceftazidime-Avibactam. Pharmacotherapy (2015) 0.99
Probing the penetration of antimicrobial polymyxin lipopeptides into gram-negative bacteria. Bioconjug Chem (2014) 0.99
Novel β-lactamase inhibitors: a therapeutic hope against the scourge of multidrug resistance. Front Microbiol (2013) 0.99
A new antibiotic and the evolution of resistance. N Engl J Med (2015) 0.95
Colistin and doripenem combinations against Pseudomonas aeruginosa: profiling the time course of synergistic killing and prevention of resistance. J Antimicrob Chemother (2015) 0.93
Antibiotic resistance: a public health crisis. Public Health Rep (2014) 0.92
Overcoming differences: The catalytic mechanism of metallo-β-lactamases. FEBS Lett (2015) 0.92
In vitro activity of plazomicin against 5,015 gram-negative and gram-positive clinical isolates obtained from patients in canadian hospitals as part of the CANWARD study, 2011-2012. Antimicrob Agents Chemother (2014) 0.92
Clinical pharmacodynamics of antipseudomonal cephalosporins in patients with ventilator-associated pneumonia. Antimicrob Agents Chemother (2013) 0.92
Mechanisms of plasmid segregation: have multicopy plasmids been overlooked? Plasmid (2014) 0.91
A Review of Novel Combinations of Colistin and Lipopeptide or Glycopeptide Antibiotics for the Treatment of Multidrug-Resistant Acinetobacter baumannii. Infect Dis Ther (2014) 0.91
Assessment of panobacumab as adjunctive immunotherapy for the treatment of nosocomial Pseudomonas aeruginosa pneumonia. Eur J Clin Microbiol Infect Dis (2014) 0.90
Comparing the Outcomes of Patients With Carbapenemase-Producing and Non-Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae Bacteremia. Clin Infect Dis (2016) 0.90
The Ethical Significance of Antimicrobial Resistance. Public Health Ethics (2015) 0.90
Potent and broad-spectrum antibacterial activity of indole-based bisamidine antibiotics: synthesis and SAR of novel analogs of MBX 1066 and MBX 1090. Bioorg Med Chem (2013) 0.89
The clinical impact of multidrug-resistant gram-negative bacilli in the management of septic shock. Virulence (2013) 0.89
Endless Resistance. Endless Antibiotics? Medchemcomm (2015) 0.88
Imaging the distribution of polymyxins in the kidney. J Antimicrob Chemother (2014) 0.88
Antimicrobial agents - optimising the ecological balance. BMC Med (2016) 0.88
Distinctive Binding of Avibactam to Penicillin-Binding Proteins of Gram-Negative and Gram-Positive Bacteria. Antimicrob Agents Chemother (2015) 0.87
Nanomedicine in the Management of Microbial Infection - Overview and Perspectives. Nano Today (2014) 0.87
Critical evaluation of ceftolozane-tazobactam for complicated urinary tract and intra-abdominal infections. Ther Clin Risk Manag (2016) 0.87
Plasmid-Mediated Antibiotic Resistance and Virulence in Gram-negatives: the Klebsiella pneumoniae Paradigm. Microbiol Spectr (2015) 0.86
Chemical modulation of the biological activity of reutericyclin: a membrane-active antibiotic from Lactobacillus reuteri. Sci Rep (2014) 0.86
Significant accumulation of polymyxin in single renal tubular cells: a medicinal chemistry and triple correlative microscopy approach. Anal Chem (2015) 0.86
One cannot rule them all: Are bacterial toxins-antitoxins druggable? FEMS Microbiol Rev (2015) 0.85
The evolution of the regulatory framework for antibacterial agents. Ann N Y Acad Sci (2014) 0.85
Major pathways of polymyxin-induced apoptosis in rat kidney proximal tubular cells. Antimicrob Agents Chemother (2015) 0.84
Activities of ceftazidime, ceftaroline, and aztreonam alone and combined with avibactam against isogenic Escherichia coli strains expressing selected single β-lactamases. Diagn Microbiol Infect Dis (2015) 0.84
Lycopene attenuates colistin-induced nephrotoxicity in mice via activation of the Nrf2/HO-1 pathway. Antimicrob Agents Chemother (2014) 0.83
Rapid cytometric antibiotic susceptibility testing utilizing adaptive multidimensional statistical metrics. Anal Chem (2015) 0.82
Peptide array based discovery of synthetic antimicrobial peptides. Front Microbiol (2013) 0.82
Targeted Treatment for Bacterial Infections: Prospects for Pathogen-Specific Antibiotics Coupled with Rapid Diagnostics. Tetrahedron (2015) 0.82
Public funding of clinical-stage antibiotic development in the United States and European Union. Health Secur (2015) 0.82
Challenges and solutions for clinical development of new antibacterial agents: results of a survey among pharmaceutical industry professionals. Antimicrob Agents Chemother (2015) 0.81
Treatment for infections with carbapenem-resistant Enterobacteriaceae: what options do we still have? Crit Care (2014) 0.81
An NF-κB-based high-throughput screen identifies piericidins as inhibitors of the Yersinia pseudotuberculosis type III secretion system. Antimicrob Agents Chemother (2013) 0.81
Origins of Yersinia pestis sensitivity to the arylomycin antibiotics and the inhibition of type I signal peptidase. Antimicrob Agents Chemother (2015) 0.80
A bioinspired peptide scaffold with high antibiotic activity and low in vivo toxicity. Sci Rep (2015) 0.80
Discovery and characterization of a novel class of pyrazolopyrimidinedione tRNA synthesis inhibitors. J Antibiot (Tokyo) (2014) 0.80
Antibiotic Restriction Might Facilitate the Emergence of Multi-drug Resistance. PLoS Comput Biol (2015) 0.79
In vitro and in vivo efficacy, toxicity, bio-distribution and resistance selection of a novel antibacterial drug candidate. Sci Rep (2016) 0.79
Antimicrobial Activity and Toxicity of the Major Lipopeptide Components of Polymyxin B and Colistin: Last-line Antibiotics against Multidrug-Resistant Gram-negative Bacteria. ACS Infect Dis (2015) 0.79
The Response Regulator BfmR Is a Potential Drug Target for Acinetobacter baumannii. mSphere (2016) 0.78
Retargeting pre-existing human antibodies to a bacterial pathogen with an alpha-Gal conjugated aptamer. J Mol Med (Berl) (2015) 0.78
Ceftolozane/Tazobactam: a new option in the treatment of complicated gram-negative infections. P T (2014) 0.78
Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Piperacillin in an In Vitro Infection Model. Antimicrob Agents Chemother (2016) 0.78
Case-case-control study of patients with carbapenem-resistant and third-generation-cephalosporin-resistant Klebsiella pneumoniae bloodstream infections. Antimicrob Agents Chemother (2014) 0.78
Clinical Efficacy of Polymyxin Monotherapy versus Nonvalidated Polymyxin Combination Therapy versus Validated Polymyxin Combination Therapy in Extensively Drug-Resistant Gram-Negative Bacillus Infections. Antimicrob Agents Chemother (2016) 0.78
Novel antimicrobial peptide-modified azithromycin-loaded liposomes against methicillin-resistant Staphylococcus aureus. Int J Nanomedicine (2016) 0.77
Polymyxin B in Combination with Rifampin and Meropenem against Polymyxin B-Resistant KPC-Producing Klebsiella pneumoniae. Antimicrob Agents Chemother (2016) 0.77
Inhibition of aminoglycoside 6'-N-acetyltransferase type Ib-mediated amikacin resistance in Klebsiella pneumoniae by zinc and copper pyrithione. Antimicrob Agents Chemother (2015) 0.77
Carbapenem-Resistant Enterobacteriaceae Infections in Children. Curr Infect Dis Rep (2016) 0.77
In vitro activity of RX-P873 against Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter baumannii. Antimicrob Agents Chemother (2015) 0.77
Emerging drugs and vaccines for candidemia. Mycoses (2014) 0.77
Challenges and future in vaccines, drug development, and immunomodulatory therapy. Ann Am Thorac Soc (2014) 0.77
Lack of new antiinfective agents: Passing into the pre-antibiotic age? World J Biol Chem (2015) 0.77
The State of Antimicrobial Stewardship in Michigan: Results of a Statewide Survey on Antimicrobial Stewardship Efforts in Acute Care Hospitals. Hosp Pharm (2015) 0.77
Randomized pharmacokinetic and drug-drug interaction studies of ceftazidime, avibactam, and metronidazole in healthy subjects. Pharmacol Res Perspect (2015) 0.77
The Modified Carbapenem Inactivation Method (mCIM) for Phenotypic Detection of Carbapenemase Production among Enterobacteriaceae. J Clin Microbiol (2017) 0.77
Singly modified amikacin and tobramycin derivatives show increased rRNA A-site binding and higher potency against resistant bacteria. ChemMedChem (2014) 0.76
Cellular Uptake and Localization of Polymyxins in Renal Tubular Cells Using Rationally Designed Fluorescent Probes. Antimicrob Agents Chemother (2015) 0.76
Optimization of synergistic combination regimens against carbapenem- and aminoglycoside-resistant clinical Pseudomonas aeruginosa isolates via mechanism-based pharmacokinetic/pharmacodynamic modeling. Antimicrob Agents Chemother (2016) 0.76
Anthelmintic closantel enhances bacterial killing of polymyxin B against multidrug-resistant Acinetobacter baumannii. J Antibiot (Tokyo) (2015) 0.76
Multiple Genetic Mutations Associated with Polymyxin Resistance in Acinetobacter baumannii. Antimicrob Agents Chemother (2015) 0.76
Small molecule deubiquitinase inhibitors promote macrophage anti-infective capacity. PLoS One (2014) 0.76
Structure-Based Design and Biological Evaluation of Triphenyl Scaffold-Based Hybrid Compounds as Hydrolytically Stable Modulators of a LuxR-Type Quorum Sensing Receptor. ACS Infect Dis (2015) 0.76
Identification of cellular targets of a series of boron heterocycles using TIPA II-A sensitive target identification platform. Bioorg Med Chem (2016) 0.75
Pipeline of Known Chemical Classes of Antibiotics. Antibiotics (Basel) (2013) 0.75
Clinical ineffectiveness of latamoxef for Stenotrophomonas maltophilia infection. Infect Drug Resist (2015) 0.75
In vitro microdialysis membrane efficiency of broad-spectrum antibiotics in combination and alone. Clin Pharmacol (2014) 0.75
Taking an Antibiotic Time-out: Utilization and Usability of a Self-Stewardship Time-out Program for Renewal of Vancomycin and Piperacillin-Tazobactam. Hosp Pharm (2015) 0.75
Pharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing. Clin Ther (2016) 0.75
Antibiotic Use and Need for Antimicrobial Stewardship in Long-Term Care. Can J Hosp Pharm (2015) 0.75
Novel imidazoline antimicrobial scaffold that inhibits DNA replication with activity against mycobacteria and drug resistant Gram-positive cocci. ACS Chem Biol (2014) 0.75
Beyond Traditional Antimicrobials: A Caenorhabditis elegans Model for Discovery of Novel Anti-infectives. Front Microbiol (2016) 0.75
Optimizing Polymyxin Combinations Against Resistant Gram-Negative Bacteria. Infect Dis Ther (2015) 0.75
Forecasting ESKAPE infections through a time-varying auto-adaptive algorithm using laboratory-based surveillance data. BMC Infect Dis (2014) 0.75
Pharmacological activation of Rap1 antagonizes the endothelial barrier disruption induced by exotoxins ExoS and ExoT of Pseudomonas aeruginosa. Infect Immun (2015) 0.75
A functional classification scheme for beta-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother (1995) 26.51
Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis (2009) 22.98
Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect (2011) 17.47
Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis (2006) 14.63
The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis (2008) 9.57
Updated functional classification of beta-lactamases. Antimicrob Agents Chemother (2009) 7.16
Combating antimicrobial resistance: policy recommendations to save lives. Clin Infect Dis (2011) 5.58
The 10 x '20 Initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin Infect Dis (2010) 5.58
Trends in antimicrobial drug development: implications for the future. Clin Infect Dis (2004) 5.23
Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis (2008) 5.05
Antibiotic-resistant bugs in the 21st century--a clinical super-challenge. N Engl J Med (2009) 4.42
The perpetual challenge of infectious diseases. N Engl J Med (2012) 3.77
Policy statement on antimicrobial stewardship by the Society for Healthcare Epidemiology of America (SHEA), the Infectious Diseases Society of America (IDSA), and the Pediatric Infectious Diseases Society (PIDS). Infect Control Hosp Epidemiol (2012) 3.76
Vital signs: carbapenem-resistant Enterobacteriaceae. MMWR Morb Mortal Wkly Rep (2013) 3.65
Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-Producing Enterobacteriaceae. Antimicrob Agents Chemother (2010) 2.54
In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermenters. J Antimicrob Chemother (2010) 2.43
White paper: recommendations on the conduct of superiority and organism-specific clinical trials of antibacterial agents for the treatment of infections caused by drug-resistant bacterial pathogens. Clin Infect Dis (2012) 2.11
Multidrug resistance among gram-negative pathogens that caused healthcare-associated infections reported to the National Healthcare Safety Network, 2006-2008. Infect Control Hosp Epidemiol (2010) 1.98
ESBLs: A Clear and Present Danger? Crit Care Res Pract (2011) 1.77
In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli. Antimicrob Agents Chemother (2010) 1.68
Antibiotics in the clinical pipeline in 2011. J Antibiot (Tokyo) (2011) 1.62
Target- and resistance-based mechanistic studies with TP-434, a novel fluorocycline antibiotic. Antimicrob Agents Chemother (2012) 1.61
In vitro antibacterial activity of the ceftazidime-avibactam (NXL104) combination against Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother (2012) 1.59
Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother (2010) 1.58
Activity of NXL104 in combination with beta-lactams against genetically characterized Escherichia coli and Klebsiella pneumoniae isolates producing class A extended-spectrum beta-lactamases and class C beta-lactamases. Antimicrob Agents Chemother (2011) 1.57
In vivo efficacy of a human-simulated regimen of ceftaroline combined with NXL104 against extended-spectrum-beta-lactamase (ESBL)-producing and non-ESBL-producing Enterobacteriaceae. Antimicrob Agents Chemother (2011) 1.57
In vitro activity of ceftazidime combined with NXL104 versus Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals (CANWARD 2009 study). Antimicrob Agents Chemother (2011) 1.50
The future of the β-lactams. Curr Opin Microbiol (2010) 1.36
In vitro activity of MK-7655, a novel β-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteria. Antimicrob Agents Chemother (2012) 1.35
Activity of ceftaroline-avibactam tested against Gram-negative organism populations, including strains expressing one or more β-lactamases and methicillin-resistant Staphylococcus aureus carrying various staphylococcal cassette chromosome mec types. Antimicrob Agents Chemother (2012) 1.33
New β-lactam antibiotics and β-lactamase inhibitors. Expert Opin Ther Pat (2010) 1.33
Combating evolution with intelligent design: the neoglycoside ACHN-490. Curr Opin Microbiol (2010) 1.26
Recommended design features of future clinical trials of antibacterial agents for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Clin Infect Dis (2010) 1.16
Activity of the siderophore monobactam BAL30072 against multiresistant non-fermenters. J Antimicrob Chemother (2009) 1.12
Can we really use ß-lactam/ß-lactam inhibitor combinations for the treatment of infections caused by extended-spectrum ß-lactamase-producing bacteria? Clin Infect Dis (2011) 1.10
In vitro activity of the siderophore monosulfactam BAL30072 against meropenem-non-susceptible Acinetobacter baumannii. J Antimicrob Chemother (2012) 1.03
In vitro activity of BAL30072 against Burkholderia pseudomallei. Int J Antimicrob Agents (2011) 1.01
In vitro activity of ceftazidime-NXL104 against 396 strains of beta-lactamase-producing anaerobes. Antimicrob Agents Chemother (2011) 0.99
In vivo and in vitro activity of the siderophore monosulfactam BAL30072 against Acinetobacter baumannii. J Antimicrob Chemother (2011) 0.98
New molecules from old classes: revisiting the development of beta-lactams. IDrugs (2009) 0.97
β-Lactam antimicrobials: what have you done for me lately? Ann N Y Acad Sci (2012) 0.92
New antimicrobial agents on the horizon. Biochem Pharmacol (2011) 0.90
Activity of ACHN-490 tested alone and in combination with other agents against Pseudomonas aeruginosa. Antimicrob Agents Chemother (2011) 0.84
Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis (2007) 24.91
Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med (2005) 23.85
Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis (2009) 22.98
Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis (2009) 18.19
Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol (2010) 17.99
Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis (2008) 16.51
Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev (2005) 15.72
Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis (2006) 14.63
International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis (2011) 12.29
Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis (2011) 11.49
The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis (2008) 9.57
Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis (2011) 9.37
Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis (2005) 9.23
Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis (2005) 8.77
Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis (2012) 8.56
Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother (2007) 7.84
Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. Clin Infect Dis (2005) 6.85
Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis (2011) 6.71
Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America. Clin Infect Dis (2010) 6.70
Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis (2013) 6.60
Combating antimicrobial resistance: policy recommendations to save lives. Clin Infect Dis (2011) 5.58
Guidelines for treatment of candidiasis. Clin Infect Dis (2003) 5.55
Three decades of beta-lactamase inhibitors. Clin Microbiol Rev (2010) 5.54
Sports medicine and ethics. Am J Bioeth (2013) 5.51
Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis (2007) 5.51
Treatment of tuberculosis. MMWR Recomm Rep (2003) 5.41
Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis (2003) 5.21
Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant (2009) 5.10
Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med (2014) 5.05
Guidelines for the management of intravascular catheter-related infections. Clin Infect Dis (2001) 4.94
Analysis of antibiotic resistance genes in multidrug-resistant Acinetobacter sp. isolates from military and civilian patients treated at the Walter Reed Army Medical Center. Antimicrob Agents Chemother (2006) 4.80
Molecular characterization of SPM-1, a novel metallo-beta-lactamase isolated in Latin America: report from the SENTRY antimicrobial surveillance programme. J Antimicrob Chemother (2002) 4.80
International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial Infections. Ann Intern Med (2004) 4.75
The rise of the Enterococcus: beyond vancomycin resistance. Nat Rev Microbiol (2012) 4.64
Practice guidelines for the management of infectious diarrhea. Clin Infect Dis (2001) 4.49
Practice guidelines for the diagnosis and management of group A streptococcal pharyngitis. Infectious Diseases Society of America. Clin Infect Dis (2002) 4.43
Comparative genome sequence analysis of multidrug-resistant Acinetobacter baumannii. J Bacteriol (2008) 4.42
Antibiotic-resistant bugs in the 21st century--a clinical super-challenge. N Engl J Med (2009) 4.42
Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project. Clin Infect Dis (2004) 4.40
Better tests, better care: improved diagnostics for infectious diseases. Clin Infect Dis (2013) 4.27
Early dissemination of NDM-1- and OXA-181-producing Enterobacteriaceae in Indian hospitals: report from the SENTRY Antimicrobial Surveillance Program, 2006-2007. Antimicrob Agents Chemother (2010) 4.03
Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol (2007) 3.93
Extended-spectrum beta-lactamases in Klebsiella pneumoniae bloodstream isolates from seven countries: dominance and widespread prevalence of SHV- and CTX-M-type beta-lactamases. Antimicrob Agents Chemother (2003) 3.92
Coccidioidomycosis. Clin Infect Dis (2005) 3.88
Characterization of blaKPC-containing Klebsiella pneumoniae isolates detected in different institutions in the Eastern USA. J Antimicrob Chemother (2009) 3.82
American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: controlling tuberculosis in the United States. Am J Respir Crit Care Med (2005) 3.82
The management of encephalitis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis (2008) 3.79
Policy statement on antimicrobial stewardship by the Society for Healthcare Epidemiology of America (SHEA), the Infectious Diseases Society of America (IDSA), and the Pediatric Infectious Diseases Society (PIDS). Infect Control Hosp Epidemiol (2012) 3.76
Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clin Infect Dis (2004) 3.75
Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia. Clin Infect Dis (2006) 3.70
Guidelines for evaluation of new fever in critically ill adult patients: 2008 update from the American College of Critical Care Medicine and the Infectious Diseases Society of America. Crit Care Med (2008) 3.67
Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis (2014) 3.67
Controlling tuberculosis in the United States. Recommendations from the American Thoracic Society, CDC, and the Infectious Diseases Society of America. MMWR Recomm Rep (2005) 3.54
Clinical practice guideline for the diagnosis and management of group A streptococcal pharyngitis: 2012 update by the Infectious Diseases Society of America. Clin Infect Dis (2012) 3.41
Endocarditis and biofilm-associated pili of Enterococcus faecalis. J Clin Invest (2006) 3.33
Molecular characterization of a beta-lactamase gene, blaGIM-1, encoding a new subclass of metallo-beta-lactamase. Antimicrob Agents Chemother (2004) 3.27
2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. Clin Infect Dis (2012) 3.22
Emergence of serine carbapenemases (KPC and SME) among clinical strains of Enterobacteriaceae isolated in the United States Medical Centers: report from the MYSTIC Program (1999-2005). Diagn Microbiol Infect Dis (2006) 3.21
Genetic basis for in vivo daptomycin resistance in enterococci. N Engl J Med (2011) 3.20
Principles of appropriate antibiotic use for acute rhinosinusitis in adults: background. Ann Intern Med (2001) 3.15
blaVIM-7, an evolutionarily distinct metallo-beta-lactamase gene in a Pseudomonas aeruginosa isolate from the United States. Antimicrob Agents Chemother (2004) 3.13
Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002). Diagn Microbiol Infect Dis (2004) 3.13
Occurrence and characterization of carbapenemase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program (2000-2004). Microb Drug Resist (2006) 3.11
Prolonged duration of initial empirical antibiotic treatment is associated with increased rates of necrotizing enterocolitis and death for extremely low birth weight infants. Pediatrics (2009) 3.05
Point: Vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis (2007) 3.05
Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system. Antimicrob Agents Chemother (2009) 2.96
Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis (2003) 2.92
Diagnosis and treatment of diabetic foot infections. Clin Infect Dis (2004) 2.92
"Stormy waters ahead": global emergence of carbapenemases. Front Microbiol (2013) 2.74
Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains. Antimicrob Agents Chemother (2005) 2.72
Large scale variation in Enterococcus faecalis illustrated by the genome analysis of strain OG1RF. Genome Biol (2008) 2.71
Influence of origin of isolates, especially endocarditis isolates, and various genes on biofilm formation by Enterococcus faecalis. Infect Immun (2004) 2.69
Antimicrobial susceptibility and epidemiology of a worldwide collection of Chryseobacterium spp: report from the SENTRY Antimicrobial Surveillance Program (1997-2001). J Clin Microbiol (2004) 2.64
First report of cfr-mediated resistance to linezolid in human staphylococcal clinical isolates recovered in the United States. Antimicrob Agents Chemother (2008) 2.63
Carbapenems: past, present, and future. Antimicrob Agents Chemother (2011) 2.61
The practice of travel medicine: guidelines by the Infectious Diseases Society of America. Clin Infect Dis (2006) 2.60
Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV medicine association of the Infectious Diseases Society of America. Clin Infect Dis (2013) 2.58
Molecular dissection of the evolution of carbapenem-resistant multilocus sequence type 258 Klebsiella pneumoniae. Proc Natl Acad Sci U S A (2014) 2.56
Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization. Am J Pathol (2006) 2.52
Multilocus sequence typing scheme for Enterococcus faecalis reveals hospital-adapted genetic complexes in a background of high rates of recombination. J Clin Microbiol (2006) 2.49
Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998-2004). Diagn Microbiol Infect Dis (2006) 2.48
Globalization of pediatric research: analysis of clinical trials completed for pediatric exclusivity. Pediatrics (2010) 2.48
IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults. Clin Infect Dis (2012) 2.43
Antimicrobial resistance and molecular epidemiology of vancomycin-resistant enterococci from North America and Europe: a report from the SENTRY antimicrobial surveillance program. Diagn Microbiol Infect Dis (2007) 2.43
The mammalian MAPK/ERK pathway exhibits properties of a negative feedback amplifier. Sci Signal (2010) 2.40
Calcineurin controls growth, morphology, and pathogenicity in Aspergillus fumigatus. Eukaryot Cell (2006) 2.35
Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America. Clin Infect Dis (2008) 2.35
Recommendation for the assessment of tobacco craving and withdrawal in smoking cessation trials. Nicotine Tob Res (2004) 2.34
A potential virulence gene, hylEfm, predominates in Enterococcus faecium of clinical origin. J Infect Dis (2003) 2.29
Emergence of blaKPC-containing Klebsiella pneumoniae in a long-term acute care hospital: a new challenge to our healthcare system. J Antimicrob Chemother (2009) 2.28
Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program. Antimicrob Agents Chemother (2007) 2.28